company background image
NGNE logo

Neurogene NasdaqGM:NGNE Stock Report

Last Price

US$17.76

Market Cap

US$261.0m

7D

-10.1%

1Y

-42.7%

Updated

20 Jun, 2025

Data

Company Financials +

Neurogene Inc.

NasdaqGM:NGNE Stock Report

Market Cap: US$261.0m

Neurogene (NGNE) Stock Overview

A clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. More details

NGNE fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Highly volatile share price over the past 3 months compared to the US market

Makes less than USD$1m in revenue ($925K)

Earnings are forecast to decline by an average of 9.5% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years


NGNE Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Neurogene Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Neurogene
Historical stock prices
Current Share PriceUS$17.76
52 Week HighUS$74.49
52 Week LowUS$6.88
Beta0
1 Month Change1.54%
3 Month Change24.98%
1 Year Change-42.73%
3 Year Changen/a
5 Year Changen/a
Change since IPO17.62%

Recent News & Updates

Neurogene: Potential To Target Root Cause Of Rett Syndrome With NGN-401

Mar 07

Recent updates

Neurogene: Potential To Target Root Cause Of Rett Syndrome With NGN-401

Mar 07

Neurogene: Interesting CNS Disease Company, Data Coming Soon

Nov 10

Neurogene Stock: Gene Therapy Specialist May Break Chain Of Failed Mergers

Mar 26

Shareholder Returns

NGNEUS BiotechsUS Market
7D-10.1%-2.3%0.0005%
1Y-42.7%-11.7%10.0%

Return vs Industry: NGNE underperformed the US Biotechs industry which returned -11% over the past year.

Return vs Market: NGNE underperformed the US Market which returned 10.4% over the past year.

Price Volatility

Is NGNE's price volatile compared to industry and market?
NGNE volatility
NGNE Average Weekly Movement21.9%
Biotechs Industry Average Movement12.2%
Market Average Movement7.7%
10% most volatile stocks in US Market17.4%
10% least volatile stocks in US Market4.0%

Stable Share Price: NGNE's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: NGNE's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2018107Rachel McMinnwww.neurogene.com

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreements with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University.

Neurogene Inc. Fundamentals Summary

How do Neurogene's earnings and revenue compare to its market cap?
NGNE fundamental statistics
Market capUS$261.00m
Earnings (TTM)-US$80.87m
Revenue (TTM)US$925.00k
273.8x
P/S Ratio
-3.1x
P/E Ratio

Is NGNE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NGNE income statement (TTM)
RevenueUS$925.00k
Cost of RevenueUS$65.13m
Gross Profit-US$64.20m
Other ExpensesUS$16.67m
Earnings-US$80.87m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-5.67
Gross Margin-6,940.76%
Net Profit Margin-8,742.70%
Debt/Equity Ratio0%

How did NGNE perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/20 11:59
End of Day Share Price 2025/06/20 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Neurogene Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Evan SeigermanBMO Capital Markets Equity Research
Keith TapperBMO Capital Markets Equity Research